Where digital and life sciences converge to create transformational technology.
Digitalisation, combined with new manufacturing processes, automation, and therapeutics is transforming health in new and exciting ways to achieve personalised medicine, enabling our New Zealand companies to compete on the global stage.
Hear from Ralph Highnam, PhD, Chief Executive Officer, Volpara Health, who is developing digital health solutions for personalised, high-quality breast cancer screening based on objective measurements of breast density, compression and radiation dose. Volpara is an ASX-listed company.
Cost: NZTech or BioTech members – free / non-members $35 (inc all taxes and fees)